Liquidia

Liquidia has entered into a global settlement agreement with United Therapeutics, thereby ending all patent litigation. Supply of PAH patients with the dry‑powder formulation Yutrepia remains fully uninterrupted. Liquidia will not appeal and has removed the PH-ILD indication from the product information. » Więcej na finanzen.net

Liquidia said at the Wells Fargo Healthcare Conference that YUTREPIA generated $170 million in revenue in Q2 2026 and that quarterly sales have increased by about $40 million in each of the past three quarters. About 75% of prescriptions are for treatment‑naive patients, and the company reported EBITDA of roughly $100 million, net income of about $80 million and an additional $60 million of cash flow in the quarter. Liquidia is expanding its commercial and clinical programs with 8–10 planned studies in the next 12 months, plans L606 as a follow‑on program, expects long‑term revenue above $1 billion, but faces an outstanding patent ruling. » Więcej na de.investing.com

The Summers Value Fund named Liquidia Corporation a top contributor after the Yutrepia launch continued to exceed investor expectations and is expected to sustain momentum. The fund expects a near-term favorable resolution of litigation that could unlock further gains. Liquidia shares are up 141.61% over the past year (down 22.08% in the past month) and the company has a market capitalization of $6.24 billion. » Więcej na finance.yahoo.com